All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What is the rationale for using BET inhibitors to treat myelofibrosis?

Dec 15, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What is the rationale for using bromodomain and extraterminal (BET) inhibitors to treat myelofibrosis?

What is the rationale for using BET inhibitors to treat myelofibrosis?

Harrison opens by discussing the unmet needs for patients with myelofibrosis who are unresponsive or intolerant to typical treatments such as ruxolitinib. The clinical applications of BET inhibitors are summarized, including the targeting of nuclear factor kappa B pathways, megakaryopoiesis, and erythropoiesis. Harrison concludes by highlighting the recent advancements in BET inhibitors for this indication and the latest updates published at the ASH Annual Meeting and Exposition.